UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 10-K

                                  ANNUAL REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     For the fiscal year ended                      Commission file number
        September 30, 2005                               33-27042-NY
     -------------------------                      ----------------------

                         BARRINGTON SCIENCES CORPORATION
                         -------------------------------
               (Formerly known as: Financial Express Corporation)
             (Exact name of registrant as specified in its charter)

                                     Nevada
         (State or other jurisdiction of incorporation or organization)

                 Nevada                               93-0996537
        (State of Incorporation)          (I.R.S. Employer Identification No.)

           1107 Bennet Drive
Port Coquitlam, British Columbia, Canada               V3C 6H2
(Address of principal executive offices)              (Zip Code)

                  Registrant's telephone number: (604) 868-7400

           Securities registered pursuant to Section 12(b) of the Act:
                NONE                                    NONE
       (Title of Each Class)                    (Name of Each Exchange
                                                 on which Registered)

          Securities registered pursuant to Section 12 (g) of the Act:
                                     Common
                                (Title of Class)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports) and (2) has been subject to such filing
requirements for the past 90 days.

         (1)  Yes [X] No [ ]                  (2)  Yes [X] No [ ]


Indicate by check mark if the registrant is a well-known seasoned issuer, as
defined in Rule 405 of the Securities Act. Yes[ ] No [X]

Indicate by check mark whether the registrant is a large accelerated filer, an
accelerated filer, or a non-accelerated filer. See definition of "accelerated
filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check
one):

Large accelerated filer [ ]   Accelerated filer [ ]   Non-accelerated filer [X]

Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Act). Yes [X] No [ ]

<PAGE>

The number of shares of the Common Stock of the registrant outstanding as of
September 30, 2005 was 24,379,977. The aggregate common stock held by
non-affiliates on September 30, 2005 was 10,394,036.
























                                       2
<PAGE>

                                 FORM 10-K INDEX

                                     PART I


Item 1.  Description of the Business                                          4

Item 2.  Properties                                                           4

Item 3.  Legal Proceedings                                                    4

Item 4.  Submission of Matters to a Vote of Security Holders                  4


                                     PART II

Item 5.  Market for Registrant's Common Equity                                4
           and Related Stockholders Matters

Item 6.  Selected Financial Matters                                           4

Item 7.  Management's Discussion and Analysis of Financial
           Condition and Results of Operations                                5

Item 7A. Quantitative and Qualitative Disclosures About Market Risk           5

Item 8.  Financial Statements and Supplementary Data                          5

Item 9.  Changes in and Disagreements with Accountants
           on Accounting and Financial Disclosure                             5


                                    PART III

Item 10. Directors and Executive Officers of Registrant                       6

Item 11. Executive Compensation                                               8

Item 12. Security Ownership of Certain Beneficial Owners and Management       8

Item 13. Certain Relationships and Related Transactions                       8

                                     PART IV

Item 15. Exhibits, Financial Statement Schedules, and Reports on Form 8-K     9

Financial Statements

Signatures

Officer Certifications


                                        3
<PAGE>

Item 1. Description of the Business
        ---------------------------

GENERAL


The company currently has no business.

The operation in China is discontinued and all activity relating to the rapid
test business has stopped.

The Company currently has no full time employees. The Company uses the part time
services of 2 individuals.

AVAILABLE INFORMATION

The Company files annual and quarterly reports (Forms 10-K and 10-Q with the
U.S. Securities and Exchange Commission and such other supplemental current
reports (Form 8-K) as may be required or appropriate from time to time.

These reports may be found at http://www.sec.gov/edgar.shtml.

Item 2. Properties
        ----------

The Company does not currently lease or own any properties.

Item 3. Legal Proceedings
        -----------------

None

Item 4. Submission of Matters to a Vote of Security Holders
        ---------------------------------------------------

None

                                     PART II

Item 5. Market for Registrant's Common Equity and Related Stockholder Matters
        ---------------------------------------------------------------------

                             (A) Stock transactions

The following summarizes stock transactions by the Company during 2004 and 2005.

From October 1, 2004 to September 30, 2005 the company issued 98,500 common
shares for $98,500. Total shares outstanding at September 30, 2005 24,379.977
Common Shares. For additional detail see shareholder Equity Section of the
financial statements.

Item 6. Selected Financial Data
        -----------------------

                        2005          2004
                        ----          ----
Revenues                   0             0

Loss                 (46,059)     (403,297)

Net Loss Per Share      0.00          0.02

Working Capital     (122,327)     (174,767)


See financial statements and notes for more detail.

                                       4
<PAGE>

Item 7. Management's Discussion and Analysis of Financial Condition and
        Results of Operations
        ---------------------------------------------------------------

LIQUIDITY.

The Company currently has a short-term liquidity problem, as evidenced by its
current working capital deficit of $122,327. However, management believes that
it will able to settle all liabilities to management and others by issuing
shares or writing off amounts owed.

OPERATIONS.

The Company had no material operations in 2005. In 2005, the Company incurred
operating expenses of $46,059. These expenses consisted primarily of $20,400 for
consulting fees, $8,882 for travel and write loss on foreign exchange of
$10,713.

BUSINESS PLANS FOR 2005/2006

The company is actively seeking a business opportunity. It is looking to secure
a merger or vend in of an operating business that will allow the company to move
forward.


Item 7A. Quantitative and Qualitative Disclosures About Market Risk
         ----------------------------------------------------------

None

The Company does not hold any material market risk sensitive instruments.



Item 8. Financial Statements and Supplementary Data
        -------------------------------------------

Reference is made to the financial statements included later in this report
after Item 15.


Item 9. Changes in and Disagreements with Accountants on Accounting and
        Financial Disclosure
        ---------------------------------------------------------------

None


Item 9A. Controls and Procedures
         -----------------------

(At the present time the company has no controls or procedures but will initiate
them once it is in business.

                                        5
<PAGE>

                                    PART III

Item 10. Directors and Executive Officers of the Registrant
         --------------------------------------------------

The following individuals currently serve as the Directors and executive
officers of the Registrant. Each Director serves for a term of one year or until
their successors have been elected at the annual meeting of shareholders in the
year each director's term expires. The year each director's term expires is
noted below. Under the Company's Articles of Incorporation, three-year staggered
terms are authorized. At the next annual shareholders meeting, it is anticipated
that Directors will be nominated for terms of one, two and three years to
implement this staggered Board provision.

Name                           Age    Position
----                           ---    --------

Phil E. Pierce                 76     Chairman, and Director Term expires 2006
                                      Mr. Pierce resigned December 6, 2006

George Moore                   63     President & Chief Executive Officer and
                                      Director Term Expires 2006

Dr. A.E.J. Reynolds            57     Director Term Expires 2006

Lorne Broten C.M.A., CMC       64     CFO and Director Term Expires 2006

The Officers are elected annually by the Directors and serve at the discretion
of the Board of Directors


George Moore
------------
President & Chief Executive Officer & Director

In 1982, Mr. Moore was a founder of Uni-Ray Inc., a consulting company and was a
Senior Partner until 1992. His client list included many well-known
international companies such as IBM, Xerox, Nortel, Decorating Den Systems and
Travelodge. In 1993, he served as the Executive Director of the foundation for
the Advancement of Canadian Entrepreneurship. From 1994 to 1996, he served as
Director of Franchise Development for Decorating Den Systems Inc. From 1996 to
1999, Mr. Moore was Manager of Business Development, Western Canada, for
Travelodge Canada. In 1999, he joined the original Barrington Sciences
Corporation and served as its President until the fall of 2001. From 2001 to the
present he has served as President and CEO of BSC.


Dr. A.E.J. Reynolds
-------------------
President ABP Diagnostics Ltd and Director

Dr. Reynolds was with Dixon Group PLC, in the position of the General Sales
Manager, Regional Manager and Commercial Manager from 1977 to 1990. From 1990 to
1993 he was Managing Director of Crawford Door Limited and Managing Director of
Eco Carpet Tiles (UK) Ltd from 1996 to 1998. Dr. Reynolds is operating a awning
business in the UK. Dr, Reynolds has a Master of Business Administration and a
Doctor of Business Administration.

                                        6
<PAGE>

Lorne H. A. Broten, C.M.A. CMC
------------------------------
CFO and Director

Mr. Broten has been a self employed Management Consultant since 1967. Over the
past five years he has been involved in two start-up companies, Barrington
Sciences Corporation and a privately owned technology company. In addition he
has had a number of consulting jobs for private companies. Mr. Broten is a
Certified Management Accountant and a Certified Management Consultant.



Section 16(a) Beneficial Ownership Reporting Compliance.

To the best of Registrant's knowledge, based solely upon a review of Forms 3 and
4 and amendments thereto furnished to Registrant pursuant to Rule 16a-3(e)
during the Company's most recent fiscal year (2005) and Form 5 and amendments
thereto furnished to the Registrant with respect to its most recent fiscal year,
the persons in the following table served as a director or officer of the
Company or owned more than 10 percent of any class of Registrant's equity
securities during Registrant's fiscal year ended September 30, 2005.

During 2005 and through the date of the filing of this Form 10-K, there has been
no trading of the Company's Common Stock or any other securities issued by the
Company. Although the Company will continue to voluntarily file Form 10Q's for
quarters ending during 2005 and has filed a Form 10-K for 2004, the Company is
not aware of any filing by the Directors, Officers or 10% shareholders until
after the acquisition of Barrington was closed as of December 31, 2002.

The Company believes that all of its Officers and Directors are now current on
their filings of applicable forms.

The following table lists all of the Company Officers, Directors and known 10%
or more shareholders during 2005.

<TABLE>
<CAPTION>
<S> <C> <C>

Name                Offices Held in 2005                     Forms Filed
-----------------------------------------------------------------------------------
Phil Pearce         Director                                 Form 3, March 26, 2003
                    Resigned as President & Treasurer
                    December 13, 2002.
                    He resigned as Director Dec 6, 2006

George Moore        President & CEO, Director from           Form 3, March 26, 2003
                    Dec. 13, 2002

Charles Payne       VP Investor Relations, Secretary,        Form 3, March 26, 2003
                    Director From Dec 13, 2002
                    He resigned as a Director July 26, 2005

Lorne Broten        CFO, Treasurer Director From             Form 3, March 26, 2003
                    December 13, 2002

Dr. Tony Reynolds   Director from December 13, 2002          Form 3, March 26, 2003


                                       7
<PAGE>

Item 11. Executive Compensation
         ----------------------

The Company did not pay any compensation to its Officers or Directors during
2005.

                                  Annual Compensation                Long-Term Compensation
                              ----------------------------  ----------------------------------------
                                                              Awards                      Payouts
                                                              ------                      -------
                                                 All Other
Name and            Year/                        Compen-    Restricted   Securities
Principle           term of                      sation       Stock      underlying                     All Other
Position            service   Salary     Bonus   (fees)       Awards     SARs/Options   LTIP Payouts    Compensation
--------            -------   ------     -----   ------       ------     ------------   ------------    ------------

George Moore, CEO   2005                         $16,800 *


----------
     * Consulting fees.

</TABLE>

The Chief Executive Officer has not received any other compensation than that
reported above, including any options or other rights to acquire any stock or
other interest in the Company. Neither the Chief Executive Officer nor any other
executive officer or Director of the Company holds any such rights as of the
date of this Form 10-K.

Item 12. Security Ownership of Certain Beneficial Owners and Management
         --------------------------------------------------------------

The following table is current as of September 30, 2005.


Name and Address of               Number of Shares of               Percentage
Beneficial Owner                  Common Stock Owned                of Ownership
-------------------               -------------------               ------------

Phil E. Pearce                       1,725,000                           7.1%
6624 Greenleaf Court
Charlotte, NC  28270

George Moore                         3,749,633*   Note 1                15.4%
15826 - 98th Ave.,
Surrey, BC V4N 2V3

Lorne Broten                         2,289,009**  Note 1                 9.4%
1107 Bennet Dr
Port Coquitlam BC V3C 6H2

Charles Payne                        4,027,126*** Note 1                16.5%
3213 W. Wheeler St PBM 249
Seattle, WA  98199
USA

Dr. Tony Reynolds                    2,195,173                           9.0%
37 Reynolds Wharf, Coalport
Telford
Shropshire, England TF8 77HU

                                    ----------                          -----

All Officers and Directors
  and affiliates as a group         13,985,941                          57.4%


                                       8
<PAGE>

--------------

* Anne Moore his wife owns 708,000. The balance of the shares are held George
Moore.

** Marc Broten son of Lorne Broten owns 700,000 of these shares and Lorne Broten
does not have control of them. Lorne Broten Family Trust owns the balance of the
shares. Lorne Broten is not a beneficiary of the trust.

*** Of these shares 3,830,849 are owned by Udici Ltd. PO Box 150 Leeward Highway
Providenciales Turks & Caicos Islands B.W.I. Estelle Payne, wife of Charles
Payne, controls this company.


Item 13. Certain Relationships and Related Transactions
         ----------------------------------------------

     None.


Item 14. Principal Accounting Fees and Services
         --------------------------------------

     (1)  Audit Fees

          The audit was not complete until 2006 so there were no fees for the
          past two years.

          There have been no fees from the Principal Accountant

     (2)  The company does not have an audit committee.






                                     PART IV

Item 15. Exhibits, Financial Statements Schedules and Reports on Form 8-K
         ----------------------------------------------------------------

(a)  The financial statements are set forth below. Financial statement schedules
     have been omitted since they are either not required, not applicable, or
     the information is otherwise included.










                                       9
<PAGE>

                          MOORE & ASSOCIATES, CHARTERED
                            ACCOUNTANTS AND ADVISORS
                                PCAOB REGISTERED


             REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
             -------------------------------------------------------


To the Board of Directors
Barrington Science


We have audited the accompanying balance sheet of Barrington Science as of
September 30, 2005, and the related statements of operations, stockholders'
equity and cash flows from September 30, 2004 through September 30, 2005. These
financial statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.

We conducted our audits in accordance with standards of the Public Company
Accounting Oversight Board (United States). Those standards require that we plan
and perform the audits to obtain reasonable assurance about whether the
financial statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also includes assessing the accounting
principles used and significant estimates made by management, as well as
evaluating the overall financial statement presentation. We believe that our
audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Barrington Science as of
September 30, 2005 and the results of its operations and its cash flows from
September 30, 2004, through September 30, 2005, in conformity with accounting
principles generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern. The Company experienced significant
operating losses since inception totaling approximately $4,400,000. In addition,
as at September 30, 2005, the Company has a working capital deficit amounting to
approximately $65,000. The consolidated financial statements have been prepared
assuming the Company will continue to operate as a going concern which
contemplates the realization of assets and the settlement of liabilities in the
normal course of business. No adjustment has been made to the recorded amount of
assets or the recorded amount of classification of liabilities which would be
required if the Company were unable to continue its operations.


/s/ Moore & Associates, Chartered

Moore & Associates Chartered
Las Vegas, Nevada
April 13, 2007

               2675 S. Jones Blvd. Suite 109, Las Vegas, NV 89146
                       (702) 253-7511 o Fax (702) 253-7501


                                       10
<PAGE>

                BARRINGTON SCIENCES CORPORATION AND SUBSIDIARIES
                          (A Development Stage Company)
                           Consolidated Balance Sheet

                                     ASSETS
                                     ------

                                                                   September 30,
                                                                        2005
                                                                    -----------
Current assets:
Cash                                                                $    42,534
                                                                    -----------
      Total current assets                                               42,534

Property and equipment, net of accumulated
  depreciation of $44,521                                                  --

Investment in joint venture                                             335,759
                                                                    -----------


Total assets                                                        $   378,293
                                                                    ===========

                      LIABILITIES AND STOCKHOLDERS' EQUITY
                      ------------------------------------
Current liabilities:
  Bank overdraft                                                    $      --
  Accounts payable                                                      107,312
                                                                    -----------
      Total current liabilities                                         107,312

  Loans from related parties                                            393,308
  Minority interest in equity of consolidated subsidiary                   --

 Preferred stock,  $.001 par value
  25,000,000 shares authorized                                             --

 Common stock, $.0001 par value,
  100,000,000 shares authorized, 24,376,977
  shares issued and outstanding                                          24,379
 Additional paid in capital                                           4,271,654
 (Deficit) accumulated during
  development stage                                                  (4,418,360)
                                                                    -----------
                                                                       (122,327)
                                                                    -----------
                                                                    $   378,293
                                                                    ===========


                 See accompanying notes to financial statements.

                                       11
<PAGE>
<TABLE>
<CAPTION>
<S> <C> <C>

                    BARRINGTON SCIENCES CORPORATION AND SUBSIDIARIES
                              (A Development Stage Company)
                          Consolidated Statements of Operations
                         Years Ended September 30, 2005 and 2004
          For the Period From Inception (August 22, 2001) to September 30, 2005
                                       (Unaudited)

                                                                            Period From
                                                     Years Ended            Inception To
                                                    September 30,           September 30,
                                                2005            2004            2005
                                            ------------    ------------    ------------

 Sales                                      $       --      $       --      $     10,736

 Costs and Expenses
  Cost of sales                                     --              --            17,437
  Selling, general and administrative             46,059         816,586       2,414,377
  Write-down of goodwill                            --           910,249         910,249
  Write-down of intangibles and inventory           --           255,773         812,546
  Write-down of other assets                        --            69,967         233,794
                                            ------------    ------------    ------------
                                                  46,059       2,052,575       4,388,403
                                            ------------    ------------    ------------

(Loss) from operations                           (46,059)     (2,052,575)     (4,377,667)

Other income (expense)
  Interest expense                                  --           (35,123)        (40,693)
                                            ------------    ------------    ------------
                                                    --           (35,123)        (40,693)

Net (loss)                                  $    (46,059)   $ (2,087,698)   $ (4,418,360)
                                            ============    ============    ============

Per share information:
Basic and diluted (loss)
  per common share                          $      (0.00)   $      (0.09)
                                            ============    ============

Weighted average shares outstanding           24,379,977      24,278,477
                                            ============    ============


                     See accompanying notes to financial statements.

                                           12
<PAGE>

                            BARRINGTON SCIENCES CORPORATION AND SUBSIDIARIES
                                      (A Development Stage Company)
                              Statement of Changes in Stockholders' Equity
                             For The Years Ended September 30, 2005 and 2004


                                                Common Stock           Additional
                                         --------------------------      Paid-in
             ACTIVITY                      Shares         Amount         Capital        Deficit          Total
                                         -----------    -----------    -----------    -----------    -----------

Balance at inception (August 22, 2001)          --      $      --      $      --      $      --      $      --

Shares issued for cash prior to
 reverse acquisition                      14,120,332         14,120        580,419                       594,539

Shares issued for acquisitions
 May 2002 at $.31 per share                4,552,570          4,553      1,420,306                     1,424,859

Shares issued for debt conversion
 In September 2002 at $1.22 per share        952,344            952      1,162,117                     1,163,069

Net loss for the year ended
  September 30, 2002                                                                   (1,881,306)    (1,881,306)
                                         -----------    -----------    -----------    -----------    -----------
Balance September 30, 2002                19,625,246         19,625      3,162,842     (1,881,306)     1,301,161

Shares issued for cash:
  October 2002 at $.48 per share             743,796            744        361,632                       362,376
  January 2003 at $.75 per share             533,333            533        399,467                       400,000
  March 2003 at $1.00 per share                8,066              8          8,058                         8,066
  April 2003 at $1.00 per share               11,714             12         11,702                        11,714
  May 2003 at $1.00 per share                 15,000             15         14,985                        15,000
  June 2003 at $1.00 per share                12,500             13         12,488                        12,500
  July 2003 at $1.00 per share                15,000             15         14,985                        15,000

Shares issued for services in
              2003 & $.75 per share           91,266             91         68,359                        68,450

Shares issued for reverse merger with
  Financial Express Corporation            3,744,701          3,745         (3,745)                         --

Shares reacquired and cancelled             (644,105)          (644)           644

Net loss for the year ended
  September 30, 2003                                                                   (2,087,698)    (2,087,698)
                                         -----------    -----------    -----------    -----------    -----------
Balance September  30, 2003               24,156,517    $    24,157    $ 4,051,416    $(3,969,004)   $   106,569


Shares Issued for Cash
  October 2003                                 5,000              5          4,995
  November 2003                               32,460             32         32,428
  December 2003                               19,500             19         19,481
  April 2004                                   5,000              5          4,995
  July 2004                                   45,000             45         44,955
  September 2004                              15,000             15         14,985
  Issues for Finders fees                      3,000              3             (3)
Net Loss for the year ended
  September 30, 2004                                                                     (403,297)
                                         -----------    -----------    -----------    -----------    -----------
                                          24,281,477         24,281      4,173,252     (4,372,301)      (174,768)
                                         -----------    -----------    -----------    -----------    -----------


Shares Issued for Cash
  November 2004                                8,000              8          7,992
  March 2005                                  40,500             40         40,460
  June 2005                                   50,000             50         49,950
                                         -----------    -----------    -----------
                                              98,500             98         98,402
                                         -----------    -----------    -----------
Net Loss for the year ended
  September 30, 2005                                                                      (46,059)

                                          24,379,977         24,379      4,271,654    $(4,418,360)   $  (122,327)
                                         ===========    ===========    ===========    ===========    ===========


See accompanying notes to financial statements.

                                                      13
<PAGE>

                    BARRINGTON SCIENCES CORPORATION AND SUBSIDIARIES
                              (A Development Stage Company)
                          Consolidated Statements of Cash Flows
                         Years Ended September 30, 2005 and 2004
          For the Period From Inception (August 22, 2001) to September 30, 2005

                                                                               Period From
                                                        Years Ended            Inception To
                                                        September 30,          September 30,
                                                    2005           2004           2005
                                                 -----------    -----------    -----------


Net income (loss)                                $   (46,059)   $  (403,297)   $(4,418,360)
  Adjustments to reconcile net income to net
   cash provided by operating activities:
   Services provided for common stock                   --             --             --
   Depreciation                                         --          (44,521)          --
   Asset impairment losses                              --          162,949           --
Changes in assets and liabilities:
(Increase) decrease in:
   Accounts receivable                                  --             --             --
   Inventory                                            --             --             --
   Prepaid expenses                                     --             --             --
   Recoverable tax credit                               --             --             --
   Deferred charges                                     --             --             --
Increase (decrease) in:                                 --
   Accounts payable                                  (20,626)        21,486        107,312
   Bank overdraft                                       --         (132,706)          --
                                                 -----------    -----------    -----------
  Total adjustments                                  (20,626)         7,208        107,312
                                                 -----------    -----------    -----------
  Net cash provided by (used in)
   operating activities                              (66,685)      (396,089)    (4,311,048)

Cash flows from investing activities:
   Acquisition of property & equipment                  --             --             --
   Investment in joint venture (loss)                   --           64,241       (335,759)
   Additions to intangible assets                       --             --             --
   Purchase of bank indebtedness of subsidiary          --             --             --
                                                 -----------    -----------    -----------
  Net cash provided by (used in)
   financing activities                                 --           64,241       (335,759)
                                                 -----------    -----------    -----------

Cash flows from financing activities:
   Proceeds from sale of common stock                 98,500        121,960      4,296,033
   Loans from related parties                         (2,956)       219,882        393,308
                                                 -----------    -----------    -----------
  Net cash provided by (used in)
   financing activities                               95,543        341,842      4,689,341
                                                 -----------    -----------    -----------

Increase (decrease) in cash                           28,858          9,994         42,534
Cash and cash equivalents,
 beginning of period                                  13,676          3,682           --
                                                 -----------    -----------    -----------
Cash and cash equivalents,
 end of period                                   $    42,534    $    13,676    $    42,534
                                                 ===========    ===========    ===========


                                           14
</TABLE>
<PAGE>

                BARRINGTON SCIENCES CORPORATION AND SUBSIDIARIES
                 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
                        (A development stage enterprise)

                 FOR THE YEARS ENDED SEPTEMBER 30, 2005 and 2004

                                 (U.S. DOLLARS)


NOTE 1   ORGANIZATION AND NATURE OF BUSINESS

     Financial Express Corporation ("FEC") was originally incorporated in the
     State of Nevada on January 5, 1989, as Harley Equities, Inc. During
     December 2002, the Company completed its acquisition of Barrington Sciences
     International Corporation's ("BSIC") net assets, subsequently FEC changed
     its name to Barrington Sciences Corporation (together with its
     subsidiaries, the Company). The acquisition was accounted for as a reverse
     take over and the comparative amounts represent BSIC's financial position,
     results of operations and cash-flows.

     The Company is a development stage enterprise and through its subsidiaries,
     has been engaged in the research, development, manufacture and distribution
     of specialized medical diagnostic test kits.


NOTE 2   SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

     Going Concern
     -------------

     The Company experienced significant operating losses since inception
     totaling approximately $4,400,000. In addition, as at September 30, 2005,
     the Company has a working capital deficit amounting to approximately
     $65,000. The consolidated financial statements have been prepared assuming
     the Company will continue to operate as a going concern which contemplates
     the realization of assets and the settlement of liabilities in the normal
     course of business. No adjustment has been made to the recorded amount of
     assets or the recorded amount of classification of liabilities which would
     be required if the Company were unable to continue its operations.

     Management has no formal plan in place to address this concern but
     considers that the Company will be able to obtain additional funds by
     equity financing and/or related party advances, however there is no
     assurance of additional funding being available.

     Principles of Consolidation
     ---------------------------

     The consolidated financial statements include the amounts of Barrington
     Sciences Corporation and the following subsidiaries:

     ABP Diagnostics Ltd.
     Fluid Seperation Ltd. (ABP Diagnostics Ltd. owns 70%)
     Barrington Sciences Corporation SDN BHD

     All material inter-company accounts and transactions have been eliminated.
     As at September 30, 2005 all subsidiaries ceased operations and have become
     inactive.

                                       15
<PAGE>

                BARRINGTON SCIENCES CORPORATION AND SUBSIDIARIES
                 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
                        (A development stage enterprise)

                 FOR THE YEARS ENDED SEPTEMBER 30, 2005 and 2004

                                 (U.S. DOLLARS)


NOTE 2   SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

     Accounting Estimates
     --------------------

     Management uses estimates and assumptions in preparing financial statements
     in accordance with generally accepted accounting principles. Those
     estimates and assumptions affect the reported amounts of assets and
     liabilities, the disclosure of contingent assets and liabilities, and the
     reported revenues and expenses. Actual results could vary from the
     estimates that were used.

     Income Taxes
     ------------

     Provisions for income taxes are based on taxes payable or refundable for
     the current year and deferred taxes on temporary differences between the
     amount of taxable income and pretax financial income and between the tax
     basis of assets and liabilities and their reported amounts in the financial
     statements. Deferred tax assets and liabilities are included in the
     financial statements at currently enacted income tax rates applicable to
     the period in which the deferred tax assets and liabilities are expected to
     be realized or settled as prescribed in FASB Statement No. 109, Accounting
     for Income Taxes. As changes in tax laws or rates are enacted, deferred tax
     assets and liabilities are adjusted through the provision for income taxes.

     Net (Loss) per Share
     --------------------

     The Company adopted Statement of Financial Accounting Standards No. 128
     that requires the reporting of both basic and diluted (loss) per share.
     Basic (loss) per share is computed by dividing net (loss) available to
     common stockholders by the weighted average number of common shares
     outstanding for the period. Diluted (loss) per share reflects the potential
     dilution that could occur if securities or other contracts to issue common
     stock were exercised or converted into common stock. In accordance with
     FASB 128, any anti-dilutive effect on net (loss) per share is excluded.

     Disclosure about Fair Value of Financial Instruments
     ----------------------------------------------------

     The Company estimates that the fair value of all financial instruments as
     of September 30, 2005 and 2004, as defined in FASB 107, does not differ
     materially from the aggregate carrying values of its financial instruments
     recorded in the accompanying consolidated balance sheets. The estimated
     fair value amounts have been determined by the Company using available
     market information and appropriate valuation methodologies. Considerable
     judgment is required in interpreting market data to develop the estimates
     of fair value, and accordingly, the estimates are not necessarily
     indicative of the amounts that the Company could realize in a current
     market exchange.

                                       16
<PAGE>

                BARRINGTON SCIENCES CORPORATION AND SUBSIDIARIES
                 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
                        (A development stage enterprise)

                 FOR THE YEARS ENDED SEPTEMBER 30, 2005 and 2004

                                 (U.S. DOLLARS)


NOTE 2   SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

     Foreign Currency Translation
     ----------------------------

     For the Company's subsidiaries outside of the U.S., the local currency is
     the functional currency. In accordance with the Statement of Financial
     Accounting Standards (SFAS) No. 52, "Foreign Currency Translation", the
     financial statements of these subsidiaries are translated into U.S. dollars
     as follows: assets and liabilities at year-end exchange rates; income,
     expense and cash flows at average exchange rates; and stockholders' equity
     at historical exchange rates. For those subsidiaries for whch he local
     currency is the functional currency, the resulting translation adjustment
     is recorded as a component of accumulated other comprehensive income (loss)
     in the accompanying consolidated balance sheet. Translation adjustments are
     not tax-effected since they related to investments, which are permanent in
     nature.

     For certain other subsidiaries, operations are conducted primarily in U.S.
     dollars, which is therefore the functional currency. Monetary assets and
     liabilities, and the related revenue, expense, gain and loss accounts, of
     these foreign subsidiaries are re-measured at year-end exchange rates.
     Non-monetary assets and liabilities, and the related revenue, expense, gain
     and loss accounts, are re-measured at historical rates.

     Shipping and Handling Costs
     ---------------------------

     The Company's policy is to classify shipping and handling costs as part of
     sales in the consolidated statement of operations.

     New Accounting Standards
     ------------------------

     Management does not believe that any recently issued, but not yet effective
     accounting standards if currently adopted could have a material effect on
     the accompanying financial statements.


                                       17
<PAGE>

                BARRINGTON SCIENCES CORPORATION AND SUBSIDIARIES

                 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
                        (A development stage enterprise)

                 FOR THE YEARS ENDED SEPTEMBER 30, 2005 and 2004

                                 (U.S. DOLLARS)


NOTE 3   REVERSE ACQUISTION

     On December 30, 2002, The Company acquired the net assets of Barrington
     Sciences International Corporation ("BSIC") including its wholly owned
     subsidiaries in exchange for 19,701,653 common shares and 396,416 common
     share warrants of the Company. This transaction has the effect of what is
     commonly referred to as "reverse acquisition" in that the Company is the
     legal acquirer; however, BSIC is the accounting acquirer. Therefore, the
     acquisition has been accounted for as a reverse take-over of the Company by
     BSIC.

     Application of reverse take-over accounting results in the following:

     a)   The consolidated financial statements of the combined entity are
          issued under the name of Barrington Sciences Corp. (formerly FEC), but
          are considered the continuation of the financial statements of BSIC.
          However, the stated capital of the consolidated entity at September
          30, 2003 is that of BSC. This capital structure Is different from the
          capital structure appearing in the comparative financial statements
          for BSIC due to the application of reverse take-over accounting. Prior
          to the acquisition, there were 19,701,653 common shares of BSIC
          outstanding with a stated capital of $3,616,373.

     b)   As BSIC is deemed to be the acquirer for accounting purposes, its
          assets, liabilities and operations since incorporation are included in
          these financial statements at their historical carrying value. The
          operations of BSC are included from December 30, 2002.

     c)   Control of the assets and operations of BSC is considered to be
          acquired by BSIC. Immediately prior to the acquisition, there were
          3,743,900 common shares of BSC outstanding with a stated capital of
          $3,744.

     All direct costs relate to the reverse take over acquisition have been
     included in the Company's results of operations.



                                       18
<PAGE>

                BARRINGTON SCIENCES CORPORATION AND SUBSIDIARIES

                 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
                        (A development stage enterprise)

                 FOR THE YEARS ENDED SEPTEMBER 30, 2005 and 2004

                                 (U.S. DOLLARS)


NOTE 4   DEFERRED CHARGES

     During the year ended September 30, 2002, BSIC incurred the cost of $20,000
     in relation to the sale of its consolidated assets to BSC, formerly FEC.
     The costs were expensed in current year in which the sale of assets was
     completed.

     During the year ended September 30, 2003, the Company incurred the cost of
     $15,000 in relation to its plan to acquire the assets of Memco-Tec Limited
     of Guangzhou, China. The acquisition plan was abandoned and the costs were
     expensed in the year.


NOTE 5   INVESTMENT IN WEIHAI BARRINGTON BIOLOGICAL ENGINERRING CO. LTD.
         (JOINT VENTURE)

     The Company and Shangdon Weigao Group of Weihai own Weihai Barrington
     Biological Engineering Co. Ltd., the joint venture in China equally. During
     the 2003, the Company has contributed $400,000 as registered capital of the
     joint venture. The joint venture has been unable to obtain the necessary
     licenses to market its products. Consequently the joint venture was
     terminated subsequent to year-end. The liquidation proceeds are estimated
     at $324,000. Subsequent to the year-end these funds were received by the
     Company.








                                       19
<PAGE>

                BARRINGTON SCIENCES CORPORATION AND SUBSIDIARIES

                 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
                        (A development stage enterprise)

                 FOR THE YEARS ENDED SEPTEMBER 30, 2005 and 2004

                                 (U.S. DOLLARS)


NOTE 6   ACQUISITION OF ABP DIAGNOSTIC LTD.

     On May 31, 2002, the Company acquired 100% of the outstanding common stock
     of ABP Diagnostic Ltd. The results of ABP Diagnostic Ltd. operations have
     been included in the consolidated financial statements since that date. ABP
     has available technical information relating to the manufacture of a
     cassette and the assembly of a range of individual diagnostic rapid test
     kits.

     The business combination is accounted for using the purchase method. The
     fair value of the assets acquired at the date of acquisition are as
     follows:

     Current assets                           $   62,795
     Furniture, equipment and machinery          100,228
     Intangibles                                 647,662
     Goodwill                                    910,249
                                              ----------

     Net assets acquired at fair values       $1,720,934
                                              ==========

     Total consideration:
     Liabilities assumed                      $  850,208
     3,450,000 common shares of the Company      870,726
                                              ----------

                                              $1,720,934
                                              ==========


NOTE 7   RELATED PARTY TRANSATIONS

                                       2005       2004

     Due to directors and officers   $393,309   $396,266
                                     ========   ========

     The amounts due to directors and officers are non-interest bearing and have
     no set terms of repayment.

     During the years, the Company, pursuant to the terms of various management
     and service agreements, paid or made provision in the accounts for the
     payments of the following amounts to its directors and officers.

                                       2005       2004

     Management fees                 $ 16,800   $ 60,000
     Consulting fees                    3,600     47,312
                                     --------   --------

                                     $ 20,400   $107,312
                                     ========   ========

                                       20
<PAGE>

                BARRINGTON SCIENCES CORPORATION AND SUBSIDIARIES
                 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
                        (A development stage enterprise)

                 FOR THE YEARS ENDED SEPTEMBER 30, 2005 and 2004

                                 (U.S. DOLLARS)


NOTE 8   COMPARITIVE FIGURES

     Certain of the comparative figures have been restated to conform with the
     current year's presentation.





SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned, hereunto duly authorized.


BARRINGTON SCIENCES CORPORATION


By: /s/ George Moore                         Date: May 1, 2007
   ----------------------------
        George Moore
        President and CEO and Director


Pursuant to the requirements of the Securities Exchange Act of 1934, this report
has been signed by the following persons on behalf of the registrant and in the
capacities and on the date indicated.

NAME & POSITION                              DATE: May 1, 2007


/S/ George Moore
-------------------------------
    George Moore
    President CEO and Director


/S/ Lorne Broten
-------------------------------
    Lorne Broten
    CFO and Director


/S/ Dr. Anthony Reynolds
-----------------------------
    Dr. Anthony Reynolds
    Director


                                       21